340 related articles for article (PubMed ID: 31841388)
1. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
[TBL] [Abstract][Full Text] [Related]
2. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
Sugahara M; Tanaka S; Tanaka T; Saito H; Ishimoto Y; Wakashima T; Ueda M; Fukui K; Shimizu A; Inagi R; Yamauchi T; Kadowaki T; Nangaku M
J Am Soc Nephrol; 2020 Mar; 31(3):560-577. PubMed ID: 31996409
[TBL] [Abstract][Full Text] [Related]
3. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
4. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
5. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Ito M; Tanaka T; Ishii T; Wakashima T; Fukui K; Nangaku M
Kidney Int; 2020 Apr; 97(4):687-701. PubMed ID: 32033782
[TBL] [Abstract][Full Text] [Related]
6. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
[TBL] [Abstract][Full Text] [Related]
7. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
[TBL] [Abstract][Full Text] [Related]
8. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
Tanaka T; Eckardt KU
Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Saito H; Tanaka T; Sugahara M; Tanaka S; Fukui K; Wakashima T; Nangaku M
Lab Invest; 2019 Jul; 99(8):1217-1232. PubMed ID: 30952940
[TBL] [Abstract][Full Text] [Related]
10. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Fujikawa R; Nagao Y; Fujioka M; Akizawa T
Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
[TBL] [Abstract][Full Text] [Related]
11. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
[TBL] [Abstract][Full Text] [Related]
12. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
[TBL] [Abstract][Full Text] [Related]
13. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
14. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
15. Preconditioned suppression of prolyl-hydroxylases attenuates renal injury but increases mortality in septic murine models.
Schindler K; Bondeva T; Schindler C; Claus RA; Franke S; Wolf G
Nephrol Dial Transplant; 2016 Jul; 31(7):1100-13. PubMed ID: 26908768
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal.
Dallatu MK; Choi M; Oyekan AO
J Hypertens; 2013 Oct; 31(10):2043-9. PubMed ID: 23811999
[TBL] [Abstract][Full Text] [Related]
17. Enarodustat to treat anemia in chronic kidney disease.
Fukui K; Tanaka T; Nangaku M
Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease.
Qian FY; Li ZL; Guo YD; Gao HC; Gu LH; Le K; Xie CM; Wang B; Zhang ZJ
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1265-F1273. PubMed ID: 31588798
[TBL] [Abstract][Full Text] [Related]
19. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Zhou J; Li J; Rosenbaum DM; Zhuang J; Poon C; Qin P; Rivera K; Lepore J; Willette RN; Hu E; Barone FC
PLoS One; 2017; 12(9):e0184049. PubMed ID: 28880966
[TBL] [Abstract][Full Text] [Related]
20. Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
Zhang A; Nakano D; Morisawa N; Kitada K; Kittikulsuth W; Rahman A; Morikawa T; Konishi Y; Nishiyama A
J Pharmacol Sci; 2021 Jun; 146(2):98-104. PubMed ID: 33941326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]